A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy?
Background. Since neoadjuvant treatment in esophageal cancer began to become popular, a complete pathological response at the primary tumour site has been commonly reported. An issue of conflict is whether complete response in the esophageal lumen means that the esophagus is completely tumour-free....
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Pathology |
| Online Access: | http://dx.doi.org/10.1155/2015/158626 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559814895468544 |
|---|---|
| author | Sebahattin Celik Remzi Erten Abdulsamed Batur Burak Suvak |
| author_facet | Sebahattin Celik Remzi Erten Abdulsamed Batur Burak Suvak |
| author_sort | Sebahattin Celik |
| collection | DOAJ |
| description | Background. Since neoadjuvant treatment in esophageal cancer began to become popular, a complete pathological response at the primary tumour site has been commonly reported. An issue of conflict is whether complete response in the esophageal lumen means that the esophagus is completely tumour-free. Another important issue is whether lymph nodes that are retrieved from pathologically complete response cases are also tumour-free or not. There is a gap in the esophageal cancer staging system for ypT0 N2 M0 tumours that have received neoadjuvant therapy. Here, we will discuss the problem about staging of esophageal cancer associated with neoadjuvant therapy. Case. A female aged 40 years complaining of dysphagia was diagnosed as having locally advanced thoracic esophageal cancer. Neoadjuvant therapy decision was taken by oncology committee. Six weeks after neoadjuvant therapy, with a curative intention, minimal invasive surgery was performed. The pathology report was as follows. “There were no neoplastic cells in the suspected area of the esophageal mucosa upon examination with all staining. There was no cancer at resection margins. Four metastatic lymph nodes were infiltrated with squamous cell cancer.” Conclusion. Despite the growing use of neoadjuvant treatment in locally advanced esophageal cancer in world, we do not have a protocol for the evaluation of these patients’ pathology reports. We believe that new studies and new ideas are needed to resolve this dilemma associated with neoadjuvant therapy. |
| format | Article |
| id | doaj-art-29f09445e2de4f64986b7c60c1cf53b7 |
| institution | Kabale University |
| issn | 2090-6781 2090-679X |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Pathology |
| spelling | doaj-art-29f09445e2de4f64986b7c60c1cf53b72025-02-03T01:29:08ZengWileyCase Reports in Pathology2090-67812090-679X2015-01-01201510.1155/2015/158626158626A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy?Sebahattin Celik0Remzi Erten1Abdulsamed Batur2Burak Suvak3Department of General Surgery, Yüzüncü Yıl University, 65200 Van, TurkeyDepartment of Pathology, Yüzüncü Yıl University, 65200 Van, TurkeyDepartment of Radiology, Yüzüncü Yıl University, 65200 Van, TurkeyDepartment of Gastroenterology, Yüzüncü Yıl University, 65200 Van, TurkeyBackground. Since neoadjuvant treatment in esophageal cancer began to become popular, a complete pathological response at the primary tumour site has been commonly reported. An issue of conflict is whether complete response in the esophageal lumen means that the esophagus is completely tumour-free. Another important issue is whether lymph nodes that are retrieved from pathologically complete response cases are also tumour-free or not. There is a gap in the esophageal cancer staging system for ypT0 N2 M0 tumours that have received neoadjuvant therapy. Here, we will discuss the problem about staging of esophageal cancer associated with neoadjuvant therapy. Case. A female aged 40 years complaining of dysphagia was diagnosed as having locally advanced thoracic esophageal cancer. Neoadjuvant therapy decision was taken by oncology committee. Six weeks after neoadjuvant therapy, with a curative intention, minimal invasive surgery was performed. The pathology report was as follows. “There were no neoplastic cells in the suspected area of the esophageal mucosa upon examination with all staining. There was no cancer at resection margins. Four metastatic lymph nodes were infiltrated with squamous cell cancer.” Conclusion. Despite the growing use of neoadjuvant treatment in locally advanced esophageal cancer in world, we do not have a protocol for the evaluation of these patients’ pathology reports. We believe that new studies and new ideas are needed to resolve this dilemma associated with neoadjuvant therapy.http://dx.doi.org/10.1155/2015/158626 |
| spellingShingle | Sebahattin Celik Remzi Erten Abdulsamed Batur Burak Suvak A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy? Case Reports in Pathology |
| title | A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy? |
| title_full | A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy? |
| title_fullStr | A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy? |
| title_full_unstemmed | A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy? |
| title_short | A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy? |
| title_sort | dilemma in staging of esophageal cancer how should we stage ypt0 n2 m0 esophageal cancer after neoadjuvant therapy |
| url | http://dx.doi.org/10.1155/2015/158626 |
| work_keys_str_mv | AT sebahattincelik adilemmainstagingofesophagealcancerhowshouldwestageypt0n2m0esophagealcancerafterneoadjuvanttherapy AT remzierten adilemmainstagingofesophagealcancerhowshouldwestageypt0n2m0esophagealcancerafterneoadjuvanttherapy AT abdulsamedbatur adilemmainstagingofesophagealcancerhowshouldwestageypt0n2m0esophagealcancerafterneoadjuvanttherapy AT buraksuvak adilemmainstagingofesophagealcancerhowshouldwestageypt0n2m0esophagealcancerafterneoadjuvanttherapy AT sebahattincelik dilemmainstagingofesophagealcancerhowshouldwestageypt0n2m0esophagealcancerafterneoadjuvanttherapy AT remzierten dilemmainstagingofesophagealcancerhowshouldwestageypt0n2m0esophagealcancerafterneoadjuvanttherapy AT abdulsamedbatur dilemmainstagingofesophagealcancerhowshouldwestageypt0n2m0esophagealcancerafterneoadjuvanttherapy AT buraksuvak dilemmainstagingofesophagealcancerhowshouldwestageypt0n2m0esophagealcancerafterneoadjuvanttherapy |